GNRHR抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: PC-3 and LOVO cell lysates, Primary antibody: P10932(GNRHR Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10932(GNRHR Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of GNRHR Antibodies**

Gonadotropin-releasing hormone receptor (GNRHR) is a G protein-coupled receptor critical for reproductive function. It binds GnRH, a hypothalamic decapeptide, to regulate the release of pituitary gonadotropins (LH and FSH), which drive gonadal steroidogenesis and gametogenesis. GNRHR dysfunction is linked to disorders like hypogonadotropic hypogonadism, infertility, and hormone-dependent cancers.

GNRHR antibodies are autoantibodies targeting this receptor, often implicated in autoimmune or idiopathic infertility. In rare cases, they disrupt GnRH signaling, impairing gonadotropin secretion and leading to hypogonadism. Such antibodies may arise spontaneously or due to molecular mimicry from infections, though their prevalence and exact mechanisms remain poorly understood.

Research on GNRHR antibodies has expanded in reproductive immunology, particularly for diagnosing autoimmune infertility or monitoring GnRH-based therapies. Experimental models using anti-GNRHR antibodies help study receptor function and GnRH signaling pathways. Therapeutic applications are also explored, including antibody-based targeting in prostate or ovarian cancers. However, clinical relevance is still emerging, requiring further validation of their diagnostic and therapeutic potential.

In summary, GNRHR antibodies represent a niche area bridging immunology and endocrinology, offering insights into reproductive disorders and novel treatment strategies.